These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 12580991

  • 1. Interaction of ibuprofen and probenecid with drug metabolizing enzyme phenotyping procedures using caffeine as the probe drug.
    Vrtic F, Haefeli WE, Drewe J, Krähenbühl S, Wenk M.
    Br J Clin Pharmacol; 2003 Feb; 55(2):191-8. PubMed ID: 12580991
    [Abstract] [Full Text] [Related]

  • 2. Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities.
    Fuchs P, Haefeli WE, Ledermann HR, Wenk M.
    Eur J Clin Pharmacol; 1999 Jan; 54(11):869-76. PubMed ID: 10027663
    [Abstract] [Full Text] [Related]

  • 3. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans.
    Rasmussen BB, Brøsen K.
    Ther Drug Monit; 1996 Jun; 18(3):254-62. PubMed ID: 8738764
    [Abstract] [Full Text] [Related]

  • 4. Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment.
    Nyéki A, Biollaz J, Kesselring UW, Décosterd LA.
    J Chromatogr B Biomed Sci Appl; 2001 May 05; 755(1-2):73-84. PubMed ID: 11393735
    [Abstract] [Full Text] [Related]

  • 5. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities.
    Hakooz NM.
    Curr Drug Metab; 2009 May 05; 10(4):329-38. PubMed ID: 19519341
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females.
    Wenk M, Todesco L, Krähenbühl S.
    Br J Clin Pharmacol; 2004 Apr 05; 57(4):495-9. PubMed ID: 15025748
    [Abstract] [Full Text] [Related]

  • 8. [Determination of caffeine metabolite for the evaluation of N-acetyltransferase, CYP1A2 and xanthine oxidase activities].
    Lu JF, Yi T, Cao XM, Zhuo HT, Ling SS.
    Yao Xue Xue Bao; 1997 Nov 05; 32(11):813-8. PubMed ID: 11596199
    [Abstract] [Full Text] [Related]

  • 9. Effects of peppermint tea consumption on the activities of CYP1A2, CYP2A6, Xanthine Oxidase, N-acetyltranferase-2 and UDP-glucuronosyltransferases-1A1/1A6 in healthy volunteers.
    Begas E, Tsioutsiouliti A, Kouvaras E, Haroutounian SA, Kasiotis KM, Kouretas D, Asprodini E.
    Food Chem Toxicol; 2017 Feb 05; 100():80-89. PubMed ID: 28011360
    [Abstract] [Full Text] [Related]

  • 10. Simultaneous action of the flavonoid quercetin on cytochrome P450 (CYP) 1A2, CYP2A6, N-acetyltransferase and xanthine oxidase activity in healthy volunteers.
    Chen Y, Xiao P, Ou-Yang DS, Fan L, Guo D, Wang YN, Han Y, Tu JH, Zhou G, Huang YF, Zhou HH.
    Clin Exp Pharmacol Physiol; 2009 Aug 05; 36(8):828-33. PubMed ID: 19215233
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites.
    Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, Teitel CH, Massengill JP, Lawsen MF, Kadlubar FF.
    Pharmacogenetics; 1992 Jun 05; 2(3):116-27. PubMed ID: 1306111
    [Abstract] [Full Text] [Related]

  • 13. The use of caffeine as a metabolic probe for human drug metabolizing enzymes.
    Miners JO, Birkett DJ.
    Gen Pharmacol; 1996 Mar 05; 27(2):245-9. PubMed ID: 8919637
    [Abstract] [Full Text] [Related]

  • 14. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
    Begas E, Kouvaras E, Tsakalof A, Papakosta S, Asprodini EK.
    Biomed Chromatogr; 2007 Feb 05; 21(2):190-200. PubMed ID: 17221922
    [Abstract] [Full Text] [Related]

  • 15. Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure.
    Jetter A, Kinzig-Schippers M, Illauer M, Hermann R, Erb K, Borlak J, Wolf H, Smith G, Cascorbi I, Sörgel F, Fuhr U.
    Eur J Clin Pharmacol; 2004 Mar 05; 60(1):17-21. PubMed ID: 14747882
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Reduction in non-glomerular renal clearance of the caffeine metabolite 1-methylxanthine by probenecid.
    Rengelshausen J, Göggelmann C, Burhenne J, Riedel KD, Mikus G, Walter-Sack I, Haefeli WE.
    Int J Clin Pharmacol Ther; 2007 Aug 05; 45(8):431-7. PubMed ID: 17725176
    [Abstract] [Full Text] [Related]

  • 18. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities.
    McQuilkin SH, Nierenberg DW, Bresnick E.
    Cancer Epidemiol Biomarkers Prev; 1995 Mar 05; 4(2):139-46. PubMed ID: 7742721
    [Abstract] [Full Text] [Related]

  • 19. Genistein alters caffeine exposure in healthy female volunteers.
    Chen Y, Xiao CQ, He YJ, Chen BL, Wang G, Zhou G, Zhang W, Tan ZR, Cao S, Wang LP, Zhou HH.
    Eur J Clin Pharmacol; 2011 Apr 05; 67(4):347-353. PubMed ID: 21222115
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.